You are not logged in.

Fluoxetine for Maintenance of Remission and to Improve Quality of Life in Patients with Crohn's Disease: a Pilot Randomized Placebo-Controlled Trial.

Mikocka-Walus, Antonina, Hughes, PA, Bampton, P, Gordon, A, Campaniello, MA, Mavrangelos, C, Stewart, BJ, Esterman, A and Andrews, JM 2017, Fluoxetine for Maintenance of Remission and to Improve Quality of Life in Patients with Crohn's Disease: a Pilot Randomized Placebo-Controlled Trial., Journal of Crohns and Colitis, vol. 11, no. 4, pp. 509-514, doi: 10.1093/ecco-jcc/jjw165.

Attached Files
Name Description MIMEType Size Downloads

Title Fluoxetine for Maintenance of Remission and to Improve Quality of Life in Patients with Crohn's Disease: a Pilot Randomized Placebo-Controlled Trial.
Author(s) Mikocka-Walus, AntoninaORCID iD for Mikocka-Walus, Antonina orcid.org/0000-0003-4864-3956
Hughes, PA
Bampton, P
Gordon, A
Campaniello, MA
Mavrangelos, C
Stewart, BJ
Esterman, A
Andrews, JM
Journal name Journal of Crohns and Colitis
Volume number 11
Issue number 4
Start page 509
End page 514
Total pages 6
Publisher Oxford University Press
Place of publication Oxford, Eng.
Publication date 2017-04-01
ISSN 1876-4479
Keyword(s) Antidepressants
Crohn’s disease
disease activity
mental health
quality of life
Science & Technology
Life Sciences & Biomedicine
Gastroenterology & Hepatology
Crohn's disease
INHIBITION
EFFICACY
THERAPY
COLITIS
ASTHMA
Summary BACKGROUND AND AIMS: Previous studies have shown that antidepressants reduce inflammation in animal models of colitis. The present trial aimed to examine whether fluoxetine added to standard therapy for Crohn's disease [CD] maintained remission, improved quality of life [QoL] and/or mental health in people with CD as compared to placebo. METHODS: A parallel randomized double-blind placebo controlled trial was conducted. Participants with clinically established CD, with quiescent or only mild disease, were randomly assigned to receive either fluoxetine 20 mg daily or placebo, and followed for 12 months. Participants provided blood and stool samples and completed mental health and QoL questionnaires. Immune functions were assessed by stimulated cytokine secretion [CD3/CD28 stimulation] and flow cytometry for cell type. Linear mixed-effects models were used to compare groups. RESULTS: Of the 26 participants, 14 were randomized to receive fluoxetine and 12 to placebo. Overall, 14 [54%] participants were male. The mean age was 37.4 [SD=13.2] years. Fluoxetine had no effect on inflammatory bowel disease activity measured using either the Crohn's Disease Activity Index [F(3, 27.5)=0.064, p=0.978] or faecal calprotectin [F(3, 32.5)=1.08, p=0.371], but did have modest effects on immune function. There was no effect of fluoxetine on physical, psychological, social or environmental QoL, anxiety or depressive symptoms as compared to placebo [all p>0.05]. CONCLUSIONS: In this small pilot clinical trial, fluoxetine was not superior to placebo in maintaining remission or improving QoL. [ID: ACTRN12612001067864.].
Language eng
DOI 10.1093/ecco-jcc/jjw165
Field of Research 110307 Gastroenterology and Hepatology
110319 Psychiatry (incl Psychotherapy)
1103 Clinical Sciences
Socio Economic Objective 920105 Digestive System Disorders
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2016, Oxford University Press
Persistent URL http://hdl.handle.net/10536/DRO/DU:30088615

Document type: Journal Article
Collection: School of Psychology
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 35 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Wed, 09 Nov 2016, 09:44:30 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.